amsacrine (BioDeep_00000004712)

Main id: BioDeep_00000019508

 


代谢物信息卡片


amsacrine

化学式: C21H19N3O3S (393.11470640000005)
中文名称: 安吖啶
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42
InChI: InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)

描述信息

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007364 - Intercalating Agents
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents
D000970 - Antineoplastic Agents

同义名列表

1 个代谢物同义名

amsacrine



数据库引用编号

14 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

2 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Kalirajan Rajagopal, Potlapati Varakumar, Baliwada Aparna, Gowramma Byran, Srikanth Jupudi. Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies. Journal of biomolecular structure & dynamics. 2021 Sep; 39(15):5551-5562. doi: 10.1080/07391102.2020.1798285. [PMID: 32720578]
  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • M Fieux, J-B Mélan, R Hermann, E Truy, S Tringali. The medical uses of manosonic nebulizers (AMSA®) in 2018. European annals of otorhinolaryngology, head and neck diseases. 2021 Mar; 138(2):73-76. doi: 10.1016/j.anorl.2020.06.020. [PMID: 32674996]
  • Hamid Akbari Javar, Zahra Garkani-Nejad, Gholamreza Dehghannoudeh, Hadi Mahmoudi-Moghaddam. Development of a new electrochemical DNA biosensor based on Eu3+-doped NiO for determination of amsacrine as an anti-cancer drug: Electrochemical, spectroscopic and docking studies. Analytica chimica acta. 2020 Oct; 1133(?):48-57. doi: 10.1016/j.aca.2020.07.071. [PMID: 32993873]
  • Biswajit Kundu, Subhendu K Das, Srijita Paul Chowdhuri, Sourav Pal, Dipayan Sarkar, Arijit Ghosh, Ayan Mukherjee, Debomita Bhattacharya, Benu Brata Das, Arindam Talukdar. Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity. Journal of medicinal chemistry. 2019 04; 62(7):3428-3446. doi: 10.1021/acs.jmedchem.8b01938. [PMID: 30897325]
  • M K Ibrahim, M S Taghour, A M Metwaly, A Belal, A B M Mehany, M A Elhendawy, M M Radwan, A M Yassin, N M El-Deeb, E E Hafez, M A ElSohly, I H Eissa. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors. European journal of medicinal chemistry. 2018 Jul; 155(?):117-134. doi: 10.1016/j.ejmech.2018.06.004. [PMID: 29885574]
  • Attia Afzal, Yunxi Zhong, Muhammad Sarfraz, Ying Peng, Longsheng Sheng, Zimei Wu, Jianguo Sun, Guangji Wang. Identification and characterization of in vivo metabolites of asulacrine using advanced mass spectrophotometry technique in combination with improved data mining strategy. Journal of chromatography. A. 2016 Apr; 1444(?):74-85. doi: 10.1016/j.chroma.2016.03.068. [PMID: 27040513]
  • Yi-Ping Fang, Chih-Hung Chuang, Pao-Chu Wu, Yaw-Bin Huang, Cherng-Chyi Tzeng, Yeh-Long Chen, Ya-Ting Liu, Yi-Hung Tsai, Ming-Jun Tsai. Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics. Drug design, development and therapy. 2016; 10(?):1019-28. doi: 10.2147/dddt.s97161. [PMID: 27019595]
  • Wenli Zhang, Guangji Wang, James R Falconer, Bruce C Baguley, John P Shaw, Jianping Liu, Hongtao Xu, Esther See, Jianguo Sun, Jiye Aa, Zimei Wu. Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug. Pharmaceutical research. 2015 Apr; 32(4):1451-61. doi: 10.1007/s11095-014-1551-8. [PMID: 25355460]
  • Ondřej Sedláček, Martin Hrubý, Martin Studenovský, David Větvička, Jan Svoboda, Dana Kaňková, Jan Kovář, Karel Ulbrich. Polymer conjugates of acridine-type anticancer drugs with pH-controlled activation. Bioorganic & medicinal chemistry. 2012 Jul; 20(13):4056-63. doi: 10.1016/j.bmc.2012.05.007. [PMID: 22658535]
  • Lubica Roziakova, Eva Bojtarova, Martin Mistrik, Juraj Dubrava, Jozef Gergel, Nadezda Lenkova, Beata Mladosievicova. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. Journal of experimental & clinical cancer research : CR. 2012 Feb; 31(?):13. doi: 10.1186/1756-9966-31-13. [PMID: 22321767]
  • Ramesh Kumar, Mandeep Kaur, Meena Kumari. Acridine: a versatile heterocyclic nucleus. Acta poloniae pharmaceutica. 2012 Jan; 69(1):3-9. doi: . [PMID: 22574501]
  • Yi-Ping Fang, Pao-Chu Wu, Yaw-Bin Huang, Cherng-Chyi Tzeng, Yeh-Long Chen, Yu-Han Hung, Ming-Jun Tsai, Yi-Hung Tsai. Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery. International journal of nanomedicine. 2012; 7(?):4995-5005. doi: 10.2147/ijn.s34301. [PMID: 23055719]
  • Anne T Nies, Ute Hofmann, Claudia Resch, Elke Schaeffeler, Maria Rius, Matthias Schwab. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PloS one. 2011; 6(7):e22163. doi: 10.1371/journal.pone.0022163. [PMID: 21779389]
  • Manjiri Arun Nadkarni, S N Vyas, M S Baghel, B Ravishankar. Randomized placebo-controlled trial of Mustadi Ghanavati in hyperlipidemia. Ayu. 2010 Jul; 31(3):287-93. doi: 10.4103/0974-8520.77150. [PMID: 22131728]
  • Liqun Zhang, Ying Guo, Jun Wang, Xiaofang Wang, Guangxi Han, Wanlu Ou, Yongnan Xu, Xiangdong Zhang. Assisted sonodynamic damage of bovine serum albumin by metronidazole under ultrasonic irradiation combined with photosensitive antitumor drug-Amsacrine. Journal of photochemistry and photobiology. B, Biology. 2010 Jan; 98(1):61-8. doi: 10.1016/j.jphotobiol.2009.11.005. [PMID: 20006932]
  • Michel J van Vliet, Wim J E Tissing, Edmond H H M Rings, Harma A Koetse, Frans Stellaard, Willem A Kamps, Eveline S J M de Bont. Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients. Pediatric blood & cancer. 2009 Dec; 53(7):1188-94. doi: 10.1002/pbc.22210. [PMID: 19688831]
  • Lingzhi Bao, An Xu, Liping Tong, Shaopeng Chen, Lingyan Zhu, Ye Zhao, Guoping Zhao, Erkang Jiang, Jun Wang, Lijun Wu. Activated toxicity of diesel particulate extract by ultraviolet a radiation in mammalian cells: role of singlet oxygen. Environmental health perspectives. 2009 Mar; 117(3):436-41. doi: 10.1289/ehp.0800029. [PMID: 19337519]
  • Srinivas Ganta, James W Paxton, Bruce C Baguley, Sanjay Garg. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. International journal of pharmaceutics. 2009 Feb; 367(1-2):179-86. doi: 10.1016/j.ijpharm.2008.09.022. [PMID: 18848873]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Naval Kapuriya, Kalpana Kapuriya, Xiuguo Zhang, Ting-Chao Chou, Rajesh Kakadiya, Yu-Tse Wu, Tung-Hu Tsai, Yu-Ting Chen, Te-Chang Lee, Anamik Shah, Yogesh Naliapara, Tsann-Long Su. Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage. Bioorganic & medicinal chemistry. 2008 May; 16(10):5413-23. doi: 10.1016/j.bmc.2008.04.024. [PMID: 18450456]
  • Anthony M Lynch, Anuska G Mahabir, Andrea Bradford, Kate Brockhurst, Jan van Benthem, Harry van Steeg, Robert W Rees. Is MutaMouse insensitive to clastogens?. Mutation research. 2008 Apr; 652(2):145-50. doi: 10.1016/j.mrgentox.2008.01.008. [PMID: 18387845]
  • Srinivas Ganta, James W Paxton, Bruce C Baguley, Sanjay Garg. Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. Journal of pharmaceutical and biomedical analysis. 2008 Jan; 46(2):386-90. doi: 10.1016/j.jpba.2007.09.025. [PMID: 17981420]
  • Miguel López-Lázaro, Nuria Pastor, Sami S Azrak, Maria Jesús Ayuso, Felipe Cortés, Caroline A Austin. Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells. Leukemia research. 2006 Jul; 30(7):895-8. doi: 10.1016/j.leukres.2005.11.005. [PMID: 16387358]
  • William N Setzer, Glenn F Rozmus, Mary C Setzer, Jennifer M Schmidt, Bernhard Vogler, Sabine Reeb, Betsy R Jackes, Anthony K Irvine. Bioactive principles in the bark of Pilidiostigma tropicum. Journal of molecular modeling. 2006 Jul; 12(5):703-11. doi: 10.1007/s00894-005-0047-1. [PMID: 16601968]
  • Yaw-Bin Huang, Pao-Chu Wu, Ming-Wei Hsu, Yeh-Long Chen, Cherng-Chyi Tzeng, Yi-Hung Tsai. Highly sensitive analysis of the anti-tumor agent 1-[4-(furo[2,3-b]-quinolin-4-ylamino)phenyl]ethanone in rat plasma by high-performance liquid chromatography using electrochemical detection. Journal of pharmaceutical and biomedical analysis. 2005 Jul; 38(3):551-5. doi: 10.1016/j.jpba.2005.01.018. [PMID: 15925259]
  • Arnab Roy Chowdhury, Shalini Sharma, Suparna Mandal, Anindya Goswami, Sibabrata Mukhopadhyay, Hemanta K Majumder. Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. The Biochemical journal. 2002 Sep; 366(Pt 2):653-61. doi: 10.1042/bj20020098. [PMID: 12027807]
  • G L Scheffer, M C de Jong, A Monks, M J Flens, C D Hose, M A Izquierdo, R H Shoemaker, R J Scheper. Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells. British journal of cancer. 2002 Jun; 86(12):1943-50. doi: 10.1038/sj.bjc.6600354. [PMID: 12085191]
  • D Fyfe, F Raynaud, R E Langley, D R Newell, G Halbert, C Gardner, K Clayton, P J Woll, I Judson, J Carmichael. A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. Cancer chemotherapy and pharmacology. 2002 Jan; 49(1):1-6. doi: 10.1007/s00280-001-0389-z. [PMID: 11855748]
  • J M Scheltema, J C Romijn, G J van Steenbrugge, F H Schröder, G H Mickisch. Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells. Anticancer research. 2001 Sep; 21(5):3161-6. doi: NULL. [PMID: 11848468]
  • S Zhou, R Chin, P Kestell, M D Tingle, J W Paxton. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. British journal of clinical pharmacology. 2001 Aug; 52(2):129-36. doi: 10.1046/j.0306-5251.2001.01438.x. [PMID: 11488768]
  • G J Finlay, B C Baguley. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer chemotherapy and pharmacology. 2000; 45(5):417-22. doi: 10.1007/s002800051011. [PMID: 10803926]
  • J Stebbing, I E Smith. Small cell lung cancer as a cause of acute renal failure secondary to bilateral renal infiltration. Clinical oncology (Royal College of Radiologists (Great Britain)). 2000; 12(5):326-7. doi: 10.1053/clon.2000.9184. [PMID: 11315720]
  • G Lönnerholm, B M Frost, R Larsson, E Liliemark, P Nygren, C Peterson. In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia. Advances in experimental medicine and biology. 1999; 457(?):429-35. doi: 10.1007/978-1-4615-4811-9_46. [PMID: 10500819]
  • M F Ozkaynak, V I Avramis, S Carcich, J A Ortega. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. Medical and pediatric oncology. 1998 Dec; 31(6):475-82. doi: 10.1002/(sici)1096-911x(199812)31:6<475::aid-mpo3>3.0.co;2-7. [PMID: 9835899]
  • L Möllgård, U Tidefelt, B Sundman-Engberg, C Löfgren, S Lehman, C Paul. High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study. Therapeutic drug monitoring. 1998 Dec; 20(6):640-5. doi: 10.1097/00007691-199812000-00010. [PMID: 9853980]
  • C M Laurençot, G L Scheffer, R J Scheper, R H Shoemaker. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. International journal of cancer. 1997 Sep; 72(6):1021-6. doi: 10.1002/(sici)1097-0215(19970917)72:6<1021::aid-ijc17>3.0.co;2-7. [PMID: 9378536]
  • T P Hardegger, A von Rohr, A Tobler, M F Fey. Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure. Annals of hematology. 1996 May; 72(5):327-8. doi: 10.1007/s002770050180. [PMID: 8645746]
  • S M Morris, L J McGarrity, O E Domon, J J Chen, D A Casciano. Cell cycle traverse in AHH-1 tk +/- human lymphoblastoid cells exposed to the chromosomal mutagen, m-amsa. Environmental and molecular mutagenesis. 1996; 27(1):10-8. doi: 10.1002/(sici)1098-2280(1996)27:1<10::aid-em2>3.0.co;2-i. [PMID: 8625943]
  • J H Lin, F J Castora. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA. Archives of biochemistry and biophysics. 1995 Dec; 324(2):293-9. doi: 10.1006/abbi.1995.0042. [PMID: 8554321]
  • T L Su, T C Chou, J Y Kim, J T Huang, G Ciszewska, W Y Ren, G M Otter, F M Sirotnak, K A Watanabe. 9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships. Journal of medicinal chemistry. 1995 Aug; 38(17):3226-35. doi: 10.1021/jm00017a006. [PMID: 7650675]
  • A M Zagariya, L A Sitailo. The influence of antibiotics and antitumor agents on the relaxation activity of Pisum sativum leaf chloroplast topoisomerase I. Archives of biochemistry and biophysics. 1995 Jun; 320(1):177-81. doi: 10.1006/abbi.1995.1357. [PMID: 7793978]
  • S P Joel, M L Slevin. Schedule-dependent topoisomerase II-inhibiting drugs. Cancer chemotherapy and pharmacology. 1994; 34 Suppl(?):S84-8. doi: 10.1007/bf00684869. [PMID: 8070033]
  • P J Vichi, T R Tritton. Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A. Cancer research. 1993 Nov; 53(21):5237-43. doi: NULL. [PMID: 8106144]
  • P Linssen, P Brons, G Knops, H Wessels, T de Witte. Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). European journal of haematology. 1993 Mar; 50(3):149-54. doi: 10.1111/j.1600-0609.1993.tb00083.x. [PMID: 8472810]
  • A G Collett, R K Ralph. Regulation of topoisomerase II by murine mastocytoma cells. Biochimica et biophysica acta. 1992 Oct; 1132(3):259-64. doi: 10.1016/0167-4781(92)90159-w. [PMID: 1329975]
  • G Rappa, A Lorico, A C Sartorelli. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). International journal of cancer. 1992 Jul; 51(5):780-7. doi: 10.1002/ijc.2910510519. [PMID: 1377186]
  • I G Robertson, B D Palmer, J W Paxton, G J Shaw. Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse. Xenobiotica; the fate of foreign compounds in biological systems. 1992 Jun; 22(6):657-69. doi: 10.3109/00498259209053128. [PMID: 1441589]
  • C A Hurwitz, R Krance, M J Schell, V M Santana, M K Brenner, R Ribeirio, W M Roberts, H Mahmoud, J Belt, W Crom. Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital. Leukemia. 1992; 6 Suppl 2(?):39-43. doi: NULL. [PMID: 1374492]
  • W K Nishioka, R M Welsh. Inhibition of cytotoxic T lymphocyte-induced target cell DNA fragmentation, but not lysis, by inhibitors of DNA topoisomerases I and II. The Journal of experimental medicine. 1992 Jan; 175(1):23-7. doi: 10.1084/jem.175.1.23. [PMID: 1309853]
  • Z A Arlin, E J Feldman, A Mittelman, T Ahmed, C Puccio, H G Chun, P Cook, P Baskind, C Marboe, R Mehta. Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer. 1991 Sep; 68(6):1198-200. doi: 10.1002/1097-0142(19910915)68:6<1198::aid-cncr2820680603>3.0.co;2-e. [PMID: 1873770]
  • T Isoe, M Naito, R Hirai, T Tsuruo. Inhibition of ubiquitin-ATP-dependent proteolysis and ubiquitination by cisplatin. Anticancer research. 1991 Sep; 11(5):1905-9. doi: NULL. [PMID: 1662928]
  • W P Petros, J H Rodman, J Mirro, W E Evans. Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. Cancer chemotherapy and pharmacology. 1991; 27(5):397-400. doi: 10.1007/bf00688865. [PMID: 1999001]
  • R M Bremnes, E Smeland, N P Willassen, E Wist, J Aarbakke. Inhibition of 7-hydroxymethotrexate formation by amsacrine. Cancer chemotherapy and pharmacology. 1991; 28(5):377-83. doi: 10.1007/bf00685693. [PMID: 1914082]
  • J W Paxton, S N Kim, L R Whitfield. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer research. 1990 May; 50(9):2692-7. doi: . [PMID: 2328494]
  • P Kestell, J W Paxton, P C Evans, D Young, J L Jurlina, I G Robertson, B C Baguley. Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. Cancer research. 1990 Feb; 50(3):503-8. doi: NULL. [PMID: 2297692]
  • R S Stein, W R Vogler, E F Winton, H J Cohen, M R Raney, A Bartolucci. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. Leukemia research. 1990; 14(10):895-903. doi: 10.1016/0145-2126(90)90179-d. [PMID: 2259226]
  • U Jehn. New drugs in the treatment of acute and chronic leukaemia: current role of mAMSA. Bone marrow transplantation. 1989 Dec; 4 Suppl 3(?):53-8. doi: . [PMID: 2697402]
  • I Cunningham, T S Gee, L M Reich, S J Kempin, A N Naval, B D Clarkson. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 1989 Apr; 73(5):1116-22. doi: . [PMID: 2930837]
  • J W Paxton, P C Evans, J R Hardy. The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit. Cancer chemotherapy and pharmacology. 1989; 23(5):291-5. doi: 10.1007/bf00292406. [PMID: 2706733]
  • J R Hardy, V J Harvey, J W Paxton, P Evans, S Smith, W Grove, A J Grillo-Lopez, B C Baguley. Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921). Cancer research. 1988 Nov; 48(22):6593-6. doi: NULL. [PMID: 3180070]
  • C A Puccio, E J Feldman, Z A Arlin. Amsacrine is safe in patients with ventricular ectopy. American journal of hematology. 1988 Jul; 28(3):197-8. doi: 10.1002/ajh.2830280315. [PMID: 2457309]
  • P Kestell, J W Paxton, I G Robertson, P C Evans, R A Dormer, B C Baguley. Thiolytic cleavage and binding of the antitumour agent CI-921 in blood. Drug metabolism and drug interactions. 1988; 6(3-4):327-36. doi: 10.1515/dmdi.1988.6.3-4.327. [PMID: 3271644]
  • J W Paxton, J R Hardy, P C Evans, V J Harvey, B C Baguley. The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial. Cancer chemotherapy and pharmacology. 1988; 22(3):235-40. doi: 10.1007/bf00273417. [PMID: 3409457]
  • I G Robertson, P Kestell, R A Dormer, J W Paxton. Involvement of glutathione in the metabolism of the anilinoacridine antitumour agents CI-921 and amsacrine. Drug metabolism and drug interactions. 1988; 6(3-4):371-81. doi: 10.1515/dmdi.1988.6.3-4.371. [PMID: 3271646]
  • G J Finlay, W R Wilson, B C Baguley. Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures. British journal of cancer. 1987 Dec; 56(6):755-62. doi: 10.1038/bjc.1987.284. [PMID: 3435703]
  • P P Brons, J M Wessels, P C Linssen, C Haanen, P A Speth. Determination of amsacrine in human nucleated hematopoietic cells. Journal of chromatography. 1987 Nov; 422(?):175-85. doi: 10.1016/0378-4347(87)80450-4. [PMID: 2449448]
  • C Y Paul, J O Liliemark, R H Farmen, C R Franks, M Uytdenhoef, C O Peterson. Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. Therapeutic drug monitoring. 1987 Sep; 9(3):263-71. doi: 10.1097/00007691-198709000-00003. [PMID: 3672568]
  • R S Walters, H M Kantarjian, M J Keating, E H Estey, K B McCredie, E J Freireich. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer. 1987 Jul; 60(2):149-55. doi: 10.1002/1097-0142(19870715)60:2<149::aid-cncr2820600204>3.0.co;2-f. [PMID: 3474052]
  • J Markovits, Y Pommier, D Kerrigan, J M Covey, E J Tilchen, K W Kohn. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Cancer research. 1987 Apr; 47(8):2050-5. doi: NULL. [PMID: 3030540]
  • T J Van Mouwerik, P M Caines, R Ballentine. Amsacrine evaluation. Drug intelligence & clinical pharmacy. 1987 Apr; 21(4):330-4. doi: 10.1177/106002808702100403. [PMID: 3552546]
  • J W Paxton, P C Evans, R M Singh. Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits. Cancer chemotherapy and pharmacology. 1987; 20(1):13-5. doi: 10.1007/bf00252952. [PMID: 3621447]
  • R M Snapka. Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication. Molecular and cellular biology. 1986 Dec; 6(12):4221-7. doi: 10.1128/mcb.6.12.4221-4227.1986. [PMID: 3025645]
  • P Frank, R F Novak. Effects of anthrapyrazole antineoplastic agents on lipid peroxidation. Biochemical and biophysical research communications. 1986 Nov; 140(3):797-807. doi: 10.1016/0006-291x(86)90704-7. [PMID: 3778486]
  • S Wadler, J Z Fuks, P H Wiernik. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. Journal of clinical pharmacology. 1986 Sep; 26(7):491-509. doi: 10.1002/j.1552-4604.1986.tb02942.x. [PMID: 2944917]
  • R B Weiss, A J Grillo-López, S Marsoni, J G Posada, F Hess, B J Ross. Amsacrine-associated cardiotoxicity: an analysis of 82 cases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1986 Jun; 4(6):918-28. doi: 10.1200/jco.1986.4.6.918. [PMID: 3519882]
  • J W Paxton, J L Jurlina, S E Foote. The binding of amsacrine to human plasma proteins. The Journal of pharmacy and pharmacology. 1986 Jun; 38(6):432-8. doi: 10.1111/j.2042-7158.1986.tb04606.x. [PMID: 2873219]
  • Y Pommier, R E Schwartz, L A Zwelling, D Kerrigan, M R Mattern, J Y Charcosset, A Jacquemin-Sablon, K W Kohn. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer research. 1986 Feb; 46(2):611-6. doi: NULL. [PMID: 3000581]
  • J W Paxton, J L Jurlina. Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits. Cancer chemotherapy and pharmacology. 1986; 16(3):253-6. doi: 10.1007/bf00293987. [PMID: 3754493]
  • J W Paxton, S E Foote, R M Singh. The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit. Cancer chemotherapy and pharmacology. 1986; 18(3):208-12. doi: 10.1007/bf00273387. [PMID: 3802376]
  • W R Grove, L W DeLap, A J Grillo-López. CI-921: an analog of amsacrine with experimental activity against solid tumors. Investigational new drugs. 1986; 4(2):113-8. doi: 10.1007/bf00194589. [PMID: 3755424]
  • B Hellman, B S Andersson, P Slanina, A Mohammed, I Brandt, M Beran. The tissue localization of m-AMSA and its effect on thymidine incorporation in various tissues in vivo. Medical oncology and tumor pharmacotherapy. 1986; 3(2):87-94. doi: 10.1007/bf02934559. [PMID: 3755785]
  • J L Jurlina, J W Paxton. Determination of N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4 -acridinecarboxamide in plasma by high-performance liquid chromatography. Journal of chromatography. 1985 Aug; 342(2):431-5. doi: 10.1016/s0378-4347(00)84539-9. [PMID: 3840491]
  • S N Kim, J R Watkins, U Jayasekara, J A Anderson, J E Fitzgerald, F A de la Iglesia. Cardiotoxicity study of amsacrine in rats. Toxicology and applied pharmacology. 1985 Mar; 77(3):369-73. doi: 10.1016/0041-008x(85)90175-9. [PMID: 3838387]
  • J Hornedo, D A Van Echo. Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicity. Pharmacotherapy. 1985 Mar; 5(2):78-90. doi: 10.1002/j.1875-9114.1985.tb03406.x. [PMID: 2582401]
  • C G Jensen, W R Wilson, A R Bleumink. Effects of amsacrine and other DNA-intercalating drugs on nuclear and nucleolar structure in cultured V79 Chinese hamster cells and PtK2 rat kangaroo cells. Cancer research. 1985 Feb; 45(2):717-25. doi: NULL. [PMID: 3838148]
  • J W Paxton, J L Jurlina. Elimination kinetics of amsacrine in the rabbit: evidence of nonlinearity. Pharmacology. 1985; 31(1):50-6. doi: 10.1159/000138097. [PMID: 3839584]
  • J L Jurlina, A R Varcoe, J W Paxton. Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. Cancer chemotherapy and pharmacology. 1985; 14(1):21-5. doi: 10.1007/bf00552719. [PMID: 3855288]
  • D J Stewart, G Zhengang, K Lu, N Savaraj, L G Feun, M Luna, R S Benjamin, M J Keating, T L Loo. Human tissue distribution of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA). Cancer chemotherapy and pharmacology. 1984; 12(2):116-9. doi: 10.1007/bf00254602. [PMID: 6583026]
  • P C Amrein, M Coleman, F Richards, R F Poulin, I Berkowitz, B J Kennedy, M Green, R Herschkopf, S Rafla. Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study. Cancer treatment reports. 1983 Nov; 67(11):1043-4. doi: NULL. [PMID: 6688967]
  • R H Earhart, P J Elson, S N Rosenthal, R G Hahn, R E Slayton. Phase II study of PALA and AMSA in advanced renal cell carcinoma. American journal of clinical oncology. 1983 Oct; 6(5):555-60. doi: 10.1097/00000421-198310000-00008. [PMID: 6688498]
  • J L Jurlina, J W Paxton. High-performance liquid-chromatographic method for the determination of 4'-(9-acridinylamino)methanesulfon-m-anisidide in plasma. Journal of chromatography. 1983 Sep; 276(2):367-74. doi: 10.1016/s0378-4347(00)85103-8. [PMID: 6688811]
  • D L Trump, S Loening, S W Ahmed, Z Wajsman. Phase II study of amsacrine (AMSA) in previously treated patients with advanced transitional cell carcinoma of the urothelium: a National Bladder Cancer Collaborative Group A study. Cancer treatment reports. 1983 Sep; 67(9):845-6. doi: NULL. [PMID: 6688377]
  • S W Hall, J Friedman, S S Legha, R S Benjamin, J U Gutterman, T L Loo. Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). Cancer research. 1983 Jul; 43(7):3422-6. doi: NULL. [PMID: 6687834]
  • Z G Guo, N Savaraj, L G Feun, K Lu, D J Stewart, M Luna, R S Benjamin, T L Loo. Tumor penetration of AMSA in man. Cancer investigation. 1983; 1(6):475-8. doi: 10.3109/07357908309020272. [PMID: 6689404]
  • F R Ahmann, F L Meyskens, T E Moon, B G Durie, S E Salmon. In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations. Cancer research. 1982 Nov; 42(11):4495-8. doi: NULL. [PMID: 6897012]
  • W R Grove, C L Fortner, P H Wiernik. Review of amsacrine, an investigational antineoplastic agent. Clinical pharmacy. 1982 Jul; 1(4):320-6. doi: . [PMID: 6764391]
  • C T Tan, C Hancock, P G Steinherz, L J Steinherz, M Sorell, K W Chan, A Mondora, D R Miller. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma. Cancer research. 1982 Apr; 42(4):1579-81. doi: NULL. [PMID: 6895864]
  • M Przybylski. Identification of metabolism pathways of anticancer drugs by high-pressure liquid chromatography in combination with field desorption mass spectrometry. Arzneimittel-Forschung. 1982; 32(9):995-1012. doi: NULL. [PMID: 6756419]